Drug Profile


Alternative Names: Debio-0824; ShK-186

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Airmid; University of California at Irvine
  • Developer Kineta; KPI Therapeutics; Seattle Childrens Research Institute; University of California at Irvine; University of Groningen
  • Class Amides; Peptides; Proteins
  • Mechanism of Action Kv1.3 potassium channel inhibitors; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inclusion body myositis; Lupus nephritis; Vasculitis
  • Research Inflammatory bowel diseases; Multiple sclerosis
  • No development reported Autoimmune disorders; Obesity; Plaque psoriasis; Psoriatic arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Plaque-psoriasis in USA (SC, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Psoriatic-arthritis(Treatment-experienced) in USA (SC, Injection)
  • 22 May 2017 Preclinical trials in Inclusion body myositis in USA (SC), before May 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top